Dottikon ES Holding AG Logo

Dottikon ES Holding AG

Manufactures chemicals and APIs, specializing in hazardous reactions.

DESN | SW

Overview

Corporate Details

ISIN(s):
CH0582581713
LEI:
50670064H782SV8G2Z44
Country:
Switzerland
Address:
Hembrunnstrasse 17, 5605 Dottikon

Description

Dottikon ES Holding AG manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the chemical, biotech, and pharmaceutical industries. The company specializes in hazardous reactions, positioning itself as a strategic development and manufacturing partner. Its services encompass research and development, route finding, process development, and process intensification. Dottikon operates multi-ton production facilities under cGMP standards, with approvals from regulatory bodies including the FDA and Swissmedic, managing the entire product lifecycle from development to large-scale manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dottikon ES Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dottikon ES Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dottikon ES Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-06-18 N/A Executive member Sell None 19,500,000.00 CHF
2023-07-24 N/A Executive member Sell None 72,600.00 CHF
2023-06-15 N/A Executive member Sell None 85,872,280.00 CHF
2023-06-15 N/A Non-Executive member Buy None 26,000.00 CHF
2023-06-01 N/A Non-Executive member Buy None 30,240.00 CHF

Peer Companies

Arcus Biosciences, Inc. Logo
A clinical-stage biopharmaceutical company developing combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes treatments for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharmaceutical company developing medicines for cardiorenal and gastrointestinal diseases.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharmaceutical company enhancing medicines with its proprietary formulation technology.
United Kingdom
AREC
argenx SE Logo
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Develops bacteriophage therapeutics for antibiotic-resistant bacterial infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets in vitro diagnostic (IVD) tests for oncology and bacteriology.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
Clinical-stage biopharma developing oncology drugs for difficult-to-treat diseases.
United States of America
AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Biotechnology company developing RNAi therapies to treat intractable diseases.
United States of America
ARWR
ARS Pharmaceuticals, Inc. Logo
Develops and commercializes needle-free products for administering therapies.
United States of America
SPRY

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.